肿瘤异种移植模型中嵌合抗原受体T细胞的直接与间接PET/MRI成像
研究用共表达抗CD19 CAR与hSSTr2报告基因的CAR T细胞,在荷CD19阳性与阴性肿瘤的免疫缺陷小鼠中比较89Zr-DFO直接标记PET/MRI与68Ga-DOTATOC间接PET/MRI的示踪效果;直接标记仅见肝肺摄取而肿瘤未显影,间接成像可见CD19阳性肿瘤摄取,第9天最高(平均%ID 3.7%±1.0),第13天降至2.6%±0.7,伴肿瘤体积缩小。
要点
- 89Zr-DFO直接标记CAR T细胞在肝、肺可见,但CD19阳性与阴性肿瘤均未显影。
- 68Ga-DOTATOC间接成像第6至13天见CD19阳性肿瘤摄取,CD19阴性肿瘤无摄取。
- CD19阳性肿瘤68Ga-DOTATOC摄取第9天最高(平均%ID 3.7%±1.0),第13天降至2.6%±0.7。
核心结论
- 在动物模型中,PET/MRI直接与间接细胞成像均可用于CAR T细胞的体内示踪与监测;间接成像可显示CD19阳性肿瘤内CAR T细胞聚集。
研究设计与样本
- 研究论文;CAR T细胞由人外周血单个核细胞制备,共表达抗CD19 CAR与hSSTr2报告基因;免疫缺陷小鼠左侧为CD19阳性、右侧为CD19阴性人肿瘤异种移植;直接标记用89Zr-DFO,间接成像用68Ga-DOTATOC;PET/MRI直接成像于第0、1、3、7天,间接成像于第6、9、13天;第13天处死取材;直接成像小鼠n=4。
关键影像表现/征象
- 89Zr-DFO标记的CAR T细胞在所有评估时间点于小鼠肝、肺可见,但CD19阳性与阴性肿瘤均未显影,即使第7天亦未见。
- 系列68Ga-DOTATOC PET/MRI第6至13天见CAR T细胞在CD19阳性肿瘤聚集,CD19阴性肿瘤无聚集。
- CD19阳性肿瘤68Ga-DOTATOC摄取第9天最高(平均%ID 3.7%±1.0),第13天降至平均%ID 2.6%±0.7,与肿瘤体积由第9天平均195 mm3±27降至第13天平均127 mm3±43平行。
- 切除的CD19阳性肿瘤组织中CD3与hSSTr2免疫组化染色增强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Chimeric antigen receptor (CAR) T cells are a promising cancer therapy; however, reliable and repeatable methods for tracking and monitoring CAR T cells in vivo remain underexplored. Purpose To investigate direct and indirect imaging strategies for tracking the biodistribution of CAR T cells and monitoring their therapeutic effect in target tumors. Materials and Methods CAR T cells co-expressing a tumor-targeting gene (anti-CD19 CAR) and a human somatostatin receptor subtype 2 (hSSTr2) reporter gene were generated from human peripheral blood mononuclear cells. After direct labeling with zirconium 89 (89Zr)-p-isothiocyanatobenzyl-desferrioxamine (DFO), CAR T cells were intravenously injected into immunodeficient mice with a CD19-positive and CD19-negative human tumor xenograft on the left and right flank, respectively. PET/MRI was used for direct in vivo imaging of 89Zr-DFO-labeled CAR T cells on days 0, 1, 3, and 7 and for indirect cell imaging with the radiolabeled somatostatin receptor-targeted ligand gallium 68 (68Ga)-DOTA-Tyr3-octreotide (DOTATOC) on days 6, 9, and 13. On day 13, mice were euthanized, and tissues and tumors were excised. Results The 89Zr-DFO-labeled CAR T cells were observed on PET/MRI scans in the liver and lungs of mice (n = 4) at all time points assessed. However, they were not visualized in CD19-positive or CD19-negative tumors, even on day 7. Serial 68Ga-DOTATOC PET/MRI showed CAR T cell accumulation in CD19-positive tumors but not in CD19-negative tumors from days 6 to 13. Notably, 68Ga-DOTATOC accumulation in CD19-positive tumors was highest on day 9 (mean percentage injected dose [%ID], 3.7% ± 1.0 [SD]) and decreased on day 13 (mean %ID, 2.6% ± 0.7) in parallel with a decrease in tumor volume (day 9: mean, 195 mm3 ± 27; day 13: mean, 127 mm3 ± 43) in the group with tumor growth inhibition. Enhanced immunohistochemistry staining of cluster of differentiation 3 (CD3) and hSSTr2 was also observed in excised CD19-positive tumor tissues. Conclusion Direct and indirect cell imaging with PET/MRI enabled in vivo tracking and monitoring of CAR T cells in an animal model. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Bulte in this issue.
引用
- Kim SY, Soh H, Jung JH, et al. Direct and Indirect Chimeric Antigen Receptor T-Cell Imaging with PET/MRI in a Tumor Xenograft Model. Radiology. 2024. PMID: 38411517. doi:10.1148/radiol.231406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。